To improve tolerance and adherence for PI3K/AKT/mTOR inhibitors, oncology nurses should preemptively provide patients with tools like loperamide for diarrhea and non-drowsy antihistamines for rash, instructing them to use them at the very first sign of symptoms.

Clinical trials with zanidatumab revealed significant diarrhea primarily in the first cycle. The successful management strategy involves mandatory loperamide twice daily for the first seven days to improve tolerability and prevent treatment discontinuation, a crucial implementation pearl.

A subgroup analysis from Capitello-291 suggests patients treated with capivasertib in the first-line setting experienced less diarrhea and rash than those in later lines. This aligns with a broader trend where heavily pre-treated patients exhibit poorer drug tolerance. This finding supports considering potent targeted agents earlier in the treatment sequence to potentially improve tolerability and outcomes.

When using the AKT inhibitor capivasertib, preventing rash is more effective than treating it. A recommended strategy for physicians unfamiliar with the drug is to prescribe twice-daily non-drowsy antihistamines proactively for the first 6-8 weeks, as the rash is difficult to manage once it appears.

New targeted therapies like Zanidatamab and Zolbetuximab show great promise but cause significant side effects like diarrhea and nausea. Their successful clinical adoption hinges on proactive management using detailed guidelines and prophylactic medications, as toxicity can be severe enough to force treatment discontinuation despite the drug's efficacy.

The side effect profile of capivasertib is front-loaded. Key toxicities like diarrhea and rash appear quickly, leading to the majority (63%) of drug discontinuations occurring within the first three months. This highlights a critical window for proactive management and patient education to improve adherence.

Data from the SOLAR-1 trial showed that adding prophylactic antihistamines for patients taking alpelisib cut the incidence of all-grade rash in half and reduced high-grade rash by 40%. This has become a standard practice for mitigating dermatologic toxicity with this class of drugs.

To manage the significant diarrhea associated with the new drug zanidatumab, a proactive approach is critical. The successful HORIZON-GEA trial protocol included mandatory loperamide twice daily for the first seven days of cycle one, a strategy which effectively managed toxicity without leading to treatment discontinuation.

Diarrhea from the HER2-directed antibody zanidatumab is a common side effect, but it's most frequent and manageable in the first two cycles. Clinicians should proactively prescribe loperamide and educate patients, as the issue often resolves and rarely leads to treatment discontinuation.